HK1090088A1 - Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme(fge) - Google Patents

Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme(fge)

Info

Publication number
HK1090088A1
HK1090088A1 HK06110799.6A HK06110799A HK1090088A1 HK 1090088 A1 HK1090088 A1 HK 1090088A1 HK 06110799 A HK06110799 A HK 06110799A HK 1090088 A1 HK1090088 A1 HK 1090088A1
Authority
HK
Hong Kong
Prior art keywords
diagnosis
treatment
fge
sulfatase deficiency
generating enzyme
Prior art date
Application number
HK06110799.6A
Other languages
English (en)
Inventor
Kurt Von Figura
Bernhard Schmidt
Thomas Dierks
Michael W Heartlein
Andrea Ballabio
Maria Pia Cosma
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of HK1090088A1 publication Critical patent/HK1090088A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
HK06110799.6A 2003-02-11 2006-09-28 Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme(fge) HK1090088A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44774703P 2003-02-11 2003-02-11
PCT/US2004/003632 WO2004072275A2 (fr) 2003-02-11 2004-02-10 Diagnostic et traitement du deficit multiple en sulfatases ainsi que d'autres deficits en sulfatases

Publications (1)

Publication Number Publication Date
HK1090088A1 true HK1090088A1 (en) 2006-12-15

Family

ID=32869644

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06110799.6A HK1090088A1 (en) 2003-02-11 2006-09-28 Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme(fge)
HK11106227.9A HK1152336A1 (en) 2003-02-11 2011-06-16 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (fge) -(fge)
HK11106228.8A HK1152337A1 (zh) 2003-02-11 2011-06-16 同時表達硫酸酯酶和 -甲酰甘氨酸產生酶的細胞以及其方法及用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK11106227.9A HK1152336A1 (en) 2003-02-11 2011-06-16 Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (fge) -(fge)
HK11106228.8A HK1152337A1 (zh) 2003-02-11 2011-06-16 同時表達硫酸酯酶和 -甲酰甘氨酸產生酶的細胞以及其方法及用途

Country Status (18)

Country Link
US (4) US8227212B2 (fr)
EP (3) EP2325302B1 (fr)
JP (3) JP5241101B2 (fr)
CN (4) CN1759176B (fr)
AT (1) ATE534730T1 (fr)
AU (2) AU2004210936C1 (fr)
CA (1) CA2515708A1 (fr)
CY (1) CY1117346T1 (fr)
DK (2) DK2325302T3 (fr)
ES (3) ES2555056T3 (fr)
HK (3) HK1090088A1 (fr)
HU (1) HUE027210T2 (fr)
MX (2) MXPA05008533A (fr)
NZ (4) NZ542267A (fr)
PT (1) PT1592786E (fr)
SI (1) SI2325302T1 (fr)
WO (1) WO2004072275A2 (fr)
ZA (1) ZA200506378B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227212B2 (en) * 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
CA2694762A1 (fr) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Procedes et compositions destines a augmenter une activite a-iduronidase dans le snc
CA2715080C (fr) 2007-09-28 2021-09-28 Intrexon Corporation Constructions et bioreacteurs de commutation de gene theapeutique destines a l'expression de molecules biotherapeutiques, et utilisation de ceux-ci
CN105274072A (zh) * 2008-01-18 2016-01-27 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2009120611A2 (fr) * 2008-03-27 2009-10-01 The Regents Of The University Of California Marqueurs aldéhydiques et leurs utilisations dans le cadre d’une modification de protéines spécifiques d’un site
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
CA2748889A1 (fr) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions et procedes pour le transport de proteines de fusion igg-recepteur leurre a travers la barriere hemato-encephalique
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
ES2725200T3 (es) * 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
US8351868B2 (en) * 2009-11-20 2013-01-08 Motorola Solutions, Inc. Radio status indicator
EP2394667A1 (fr) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
WO2012101671A1 (fr) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Procédé de production d'iduronate 2-sulfatase recombinante humaine
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
EP4338797A3 (fr) 2011-12-02 2024-06-12 Armagen, Inc. Procédés et compositions pour augmenter l'activité d'arylsulfatase a dans le snc
US9896715B2 (en) 2011-12-20 2018-02-20 Jcr Pharmaceuticals Co., Ltd. Method for analyzing formyl glycine residue
US9603908B2 (en) 2012-03-30 2017-03-28 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate-2-sulfatase
WO2013148323A1 (fr) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Procédés d'analyse et de préparation de compositions protéiques
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2014016873A1 (fr) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Procédé de production d'alpha-galactosidase a humaine recombinante
EP3730516A1 (fr) * 2013-07-22 2020-10-28 Armagen, Inc. Procédés et compositions pour augmenter l'activité enzymatique dans le snc
EP3912635A1 (fr) * 2014-07-11 2021-11-24 Biostrategies LC Matériaux et procédés pour traiter des troubles associés aux enzymes sulfatases
MA41198A (fr) 2014-12-18 2017-10-24 Shire Human Genetic Therapies Essais d'activité enzymatique pour i2s
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2016116966A1 (fr) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Procédé de purification d'une alpha-galactosidase a recombinante humaine à partir de matériel contenant des protéines contaminantes des cellules hôtes
JPWO2016121715A1 (ja) * 2015-01-26 2017-11-02 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
WO2016126339A1 (fr) 2015-02-05 2016-08-11 R.P. Scherer Technologies, Llc Enzymes générant de la formylglycine activées et leurs procédés de production et d'utilisation
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
WO2017189432A1 (fr) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Conjugués d'anticorps et méthodes de fabrication et d'utilisation de ceux-ci
WO2018060097A1 (fr) * 2016-09-30 2018-04-05 Laboratorios Del Dr. Esteve, S. A. Vecteurs dérivés de virus adéno-associés pour le traitement de mucopolysaccharidoses
KR102471458B1 (ko) 2016-12-28 2022-11-25 제이씨알 파마 가부시키가이샤 동결건조 제제
KR102697723B1 (ko) 2017-01-18 2024-08-21 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
CA3076369A1 (fr) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Proteines de fusion comprenant des enzymes d'enzymotherapie substitutive
CN109628426B (zh) * 2019-01-02 2023-05-09 山东大学 一种δ4,5-己糖醛酸-2-o-硫酸酯酶及其编码基因与应用以及同类酶的鉴定方法
CN109781997A (zh) * 2019-01-22 2019-05-21 中国人民解放军总医院 用于诊断粘多糖病ⅱ型的生物标志物及其应用
WO2021203024A1 (fr) 2020-04-03 2021-10-07 Visterra, Inc. Conjugués molécule d'anticorps-médicament et leurs utilisations
AU2021252515A1 (en) * 2020-04-06 2022-10-27 Homology Medicines, Inc. Adeno-associated virus compositions for IDS gene transfer and methods of use thereof
CN112630430B (zh) * 2020-11-16 2021-08-27 北京美联泰科生物技术有限公司 一种定量检测uchl-1的试剂盒及其应用
CN117940144A (zh) 2021-05-27 2024-04-26 R.P.谢勒技术有限责任公司 控制含甲酰甘氨酸的多肽的切割的方法
WO2024176112A1 (fr) * 2023-02-21 2024-08-29 Takeda Pharmaceutical Company Limited Production à grande échelle d'arylsulfatase a recombinante et compositions associées

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3307A (en) 1843-10-18 Laben eddy
US307A (en) 1837-07-29 Rqss winans
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4748024A (en) 1987-04-06 1988-05-31 Endocon, Inc. Flash flow fused medicinal implants
US5674722A (en) 1987-12-11 1997-10-07 Somatix Therapy Corporation Genetic modification of endothelial cells
WO1990004788A1 (fr) 1988-10-28 1990-05-03 Genentech, Inc. Procede d'identification de domaines actifs et de residus d'acides amines dans des polypeptides et des variantes d'hormones
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
EP0804249A2 (fr) 1994-03-15 1997-11-05 Brown University Research Foundation Systeme de liberation de genes polymeres
DE69531044T2 (de) * 1994-03-16 2003-12-04 The Regents Of The University Of California, Alameda Behandlung von entzündung durch die gabe von spezifischen sulfatase-enzymen und/oder inhibitoren der sulfatierung
US5863782A (en) * 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2001018022A1 (fr) * 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 proteines humaines secretees
EP2301947A3 (fr) * 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Protéines sécrétées et utilisations associées
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
JP2002017376A (ja) * 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (fr) * 2000-02-17 2001-08-23 Incyte Genomics, Inc. Kinases humaines
JP2003527851A (ja) * 2000-03-17 2003-09-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７つのヒト卵巣および卵巣癌関連タンパク質
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20030166283A1 (en) 2000-12-21 2003-09-04 Millennium Pharmaceuticals, Inc. 22437, a novel human sulfatase and uses therefor
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
US20030147875A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
JP2005506838A (ja) 2001-08-31 2005-03-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ヒトスルファターゼファミリーメンバーｍｉｄ９００２およびその使用
US8227212B2 (en) * 2003-02-11 2012-07-24 Shire Human Genetic Therapies, Inc. Cell that expresses a sulfatase and a formylglycine generating enzyme
US8510225B2 (en) 2004-09-01 2013-08-13 Research In Motion Limited Split channel authenticity queries in multi-party dialog
CN105450838B (zh) 2014-09-01 2019-12-24 联想(北京)有限公司 一种信息处理方法及电子设备

Also Published As

Publication number Publication date
CA2515708A1 (fr) 2004-08-26
JP6007203B2 (ja) 2016-10-12
AU2004210936B2 (en) 2010-05-13
US20130028881A1 (en) 2013-01-31
HK1152336A1 (en) 2012-02-24
CN103055306A (zh) 2013-04-24
NZ570201A (en) 2011-03-31
US8227212B2 (en) 2012-07-24
ZA200506378B (en) 2006-12-27
ES2380147T3 (es) 2012-05-09
EP2325301B1 (fr) 2015-09-02
NZ603330A (en) 2015-02-27
WO2004072275A2 (fr) 2004-08-26
CN1759176B (zh) 2012-10-03
EP1592786B1 (fr) 2011-11-23
PT1592786E (pt) 2012-01-19
ES2566641T3 (es) 2016-04-14
US20130172403A1 (en) 2013-07-04
MXPA05008533A (es) 2005-10-20
CY1117346T1 (el) 2017-04-26
NZ542267A (en) 2008-12-24
NZ596420A (en) 2012-11-30
AU2004210936C1 (en) 2010-12-02
CN1759176A (zh) 2006-04-12
CN101444621A (zh) 2009-06-03
US20040229250A1 (en) 2004-11-18
DK2325302T3 (en) 2016-03-14
JP2006517412A (ja) 2006-07-27
EP2325302A8 (fr) 2012-02-22
JP5527854B2 (ja) 2014-06-25
ATE534730T1 (de) 2011-12-15
AU2010212261C1 (en) 2012-12-06
HUE027210T2 (en) 2016-10-28
SI2325302T1 (sl) 2016-05-31
AU2004210936A1 (en) 2004-08-26
EP1592786A2 (fr) 2005-11-09
WO2004072275A3 (fr) 2005-04-14
JP2012090630A (ja) 2012-05-17
HK1152337A1 (zh) 2012-02-24
AU2010212261A1 (en) 2010-09-02
ES2555056T3 (es) 2015-12-28
JP5241101B2 (ja) 2013-07-17
MX345056B (es) 2017-01-16
DK1592786T3 (da) 2012-02-13
EP2325302B1 (fr) 2016-01-06
EP2325302A1 (fr) 2011-05-25
CN103055306B (zh) 2020-10-27
CN110496230A (zh) 2019-11-26
CN101444621B (zh) 2013-11-20
AU2010212261B2 (en) 2012-04-26
JP2014131515A (ja) 2014-07-17
US20160367703A1 (en) 2016-12-22
EP1592786B8 (fr) 2012-03-21
EP2325301A1 (fr) 2011-05-25

Similar Documents

Publication Publication Date Title
HK1090088A1 (en) Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme(fge)
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
AU2002360488A1 (en) Methods and devices for detection and therapy of atheromatous plaque
RS20060320A (en) Substituted indazole-o-glucosides
TW200505458A (en) 1-amino 1h-imidazoquinolines
EP1474687A4 (fr) Mark utilises comme modificateurs de la voie p53 et procedes d'utilisation
MY142777A (en) Substituted indole-o-glucosides
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
UA87991C2 (en) Substituted indole-o-glucosides
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
WO2005021727A3 (fr) Ciblage specifique a l'isoforme de variants d'epissure
WO2005010148A3 (fr) Marks de modification de la voie pten et methodes d'utilisation
EP1436279A4 (fr) Composes chimiques
WO2004053083A3 (fr) Modulation de l'expression du facteur de transcription de fetoproteine
WO2004048524A3 (fr) Modulation de l'expression de stat2
WO2003106645A3 (fr) Modulation antisens de l'expression du corepresseur smrt
WO2005054174A3 (fr) Composes de modulation du complexe de l'enzyme de glycolyse et/ou de transaminase
WO2006072951A3 (fr) Compositions et methodes de regulation de l'apoptose
AU2003249999A1 (en) 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours
WO2003105778A3 (fr) Inhibiteurs de phosphatidylinositol-4-phosphate 5-kinase, de type ii beta, ayant une action inhibitrice sur l'angiogenese
WO2004052306A3 (fr) Modulation de l'expression de ppar-alpha

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240209